期刊： VASCULAR PHARMACOLOGY, 2021; 139 ()
Background: Emerging evidence has shown that long non-coding RNA (lncRNA) plays important roles in the development of pulmonary arterial hypertension ......
期刊： VASCULAR PHARMACOLOGY, 2021; 139 ()
Background: Upregulation of L-type voltage-gated Ca2+ (CaV1.2) channel in the arterial myocytes is a hallmark feature of hypertension. However, whethe......
期刊： VASCULAR PHARMACOLOGY, 2021; 139 ()
Circular RNAs (circRNAs) are a group of conserved noncoding RNAs. Recent reports reveal that circRNAs play vital parts in cardiovascular system, inclu......
期刊： VASCULAR PHARMACOLOGY, 2021; 138 ()
Background: Coronary slow flow (CSF) refers to coronary arteries with no obvious stenosis but have slow coronary flow without effective treatment. The......
期刊： VASCULAR PHARMACOLOGY, 2021; 138 ()
5-Hydroxytryptamine (5-HT)-dependent signaling mediated through its transporters and receptors plays important roles in chronic hypoxic pulmonary hype......
期刊： VASCULAR PHARMACOLOGY, 2021; 136 ()
Background: Vascular calcification (VC) is associated with the high morbidity and mortality of cardiovascular diseases in dialysis patients and is a p......
期刊： VASCULAR PHARMACOLOGY, 2021; 136 ()
Aim: Exsomes play a significant role in increasing pathophysiological processes by delivering their content. Recently, a variety of studies have showe......
期刊： VASCULAR PHARMACOLOGY, 2021; 136 ()
Objective: Rivaroxaban is a specific factor Xa (FXa) inhibitor for venous thromboembolism treatment. Recently, increasing evidence have reported the b......
期刊： VASCULAR PHARMACOLOGY, 2020; 130 ()
Vascular calcification (VC) is a common complication of chronic kidney disease (CKD). However, its mechanisms remain unclear. VC, similar to atheroscl......
期刊： VASCULAR PHARMACOLOGY, 2020; 131 ()
Atherosclerosis (AS) is one of the most common cardiovascular events in patients with chronic renal insufficiency (CRI). During the development of CRI......
期刊： VASCULAR PHARMACOLOGY, 2020; 132 ()
Backgrounds: Medial artery calcification (MAC) significantly contributes to the increased cardiovascular death in patients with chronic kidney disease......
期刊： VASCULAR PHARMACOLOGY, 2020; 133 ()
Atherosclerosis is a systemic chronic inflammatory disease. Many antioxidants including alpha-lipoic acid (LA), a product of lipoic acid synthase (Lia......
期刊： VASCULAR PHARMACOLOGY, 2020; 128 ()
The vascular ATP-sensitive K+ (K-ATP) channel composed of Kir6.1 and SUR2B subunits regulates cellular activity by coupling intermediary metabolism to......
期刊： VASCULAR PHARMACOLOGY, 2020; 124 ()
Metformin (Met) can improve atherosclerosis (As). Abnormal endothelin receptors [including endothelin type A (ETA) or type B (ETB) receptor] in vascul......
